US 12,230,364 B2
Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
Wei Keat Lim, Tarrytown, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Mar. 20, 2023, as Appl. No. 18/186,762.
Application 18/186,762 is a continuation of application No. 16/135,913, filed on Sep. 19, 2018, granted, now 11,640,848.
Claims priority of provisional application 62/560,955, filed on Sep. 20, 2017.
Prior Publication US 2023/0268028 A1, Aug. 24, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G16B 30/00 (2019.01); A61P 35/00 (2006.01); C12Q 1/6806 (2018.01); C12Q 1/6809 (2018.01); C12Q 1/6886 (2018.01); G16B 5/00 (2019.01); G16B 15/00 (2019.01)
CPC G16B 30/00 (2019.02) [A61P 35/00 (2018.01); C12Q 1/6806 (2013.01); C12Q 1/6809 (2013.01); C12Q 1/6886 (2013.01); G16B 5/00 (2019.02); G16B 15/00 (2019.02); C12Q 2565/519 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01)] 45 Claims
 
1. A method of treating a cancer patient with an antibody that binds to LAG3, comprising administering the antibody that binds to LAG3 to the cancer patient, whereby the cancer patient has been determined to have a tumor having a total passenger gene mutational burden that is greater than a background mutational burden of the tumor.